OBJECTIVE: To determine whether there is a difference in the
concentration of nerve growth factor (NGF) in the
cerebrospinal fluid (CSF) from patients diagnosed with primary
fibromyalgia syndrome (FM), fibromyalgia associated with other
secondary conditions (SFM), patients with other painful
conditions but lacking fibromyalgia (OTHER), and healthy
METHODS: The clinical measures of pain threshold
included the tender point index, a measure of pain threshold
intensity measured by digital pressure, and the average pain
threshold measured by dolorimetry. Concentrations of NGF in
the CSF were measured using a 2 site enzyme immunoassay.
RESULTS: The mean (+/- SEM) concentration of NGF measured in
patients with FM was significantly increased (41.8 +/- 12.7
pg/ml) compared to controls (9.1 +/- 4.1 pg/ml), but with
large variability. Concentrations of NGF is SFM (8.9 +/- 4.4
pg/ml) and OTHER (16.2 +/- 8.4 pg/ml) were not elevated
compared to controls.
CONCLUSION: The findings of increased
concentrations of NGF in patients with FM suggest a central
mechanism, involving abnormalities in neuropeptides such as
NGF, may be a factor in the pathogenesis of FM.
Giovengo SL, Russell IJ, Larson AA